Sophiris Bio Inc (SPHS) 2.51 $SPHS Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2015 at 7:19 PM

Sophiris Bio Inc (SPHS) 2.51 $SPHS

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
at The Street - Fri Nov 13, 8:36AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 71.39 (-0.90), ZFGN: 13.43 (+0.65), NWBO: 4.54 (+0.02), ZSPH: 89.56 (+0.17), SPHS: 2.51 (-0.54), RLYP: 18.96 (+1.31)

Sophiris Bio (SPHS) Stock Jumps After Drug Trial Meets Goal
at The Street - Wed Nov 11, 2:34PM CST
Sophiris Bio (SPHS) stock is increasing on heavy trading volume on Wednesday, after the company announced that its prostate drug met the goal of a Phase 3 study.
SPHS: 2.51 (-0.54)

Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
PR Newswire - Tue Nov 10, 7:18AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 "PLUS-1" study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study. PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects.
SPHS: 2.51 (-0.54)

Versartis names Dr Lars Ekman as global development advisor
M2 - Fri Sep 11, 4:58AM CDT
Biopharmaceutical company Versartis (NasdaqGS:VSAR) revealed on Thursday that it has appointed Lars Ekman, MD, PhD, as its global development advisor.
VSAR: 10.25 (+0.38), SPHS: 2.51 (-0.54), ONCE: 55.94 (-0.19)

Sophiris Bio Reports Second Quarter Financial Results
Business Wire - Thu Aug 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six months ended June 30, 2015.
SPHS: 2.51 (-0.54)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 06, 10:45AM CDT
These under-$10 stocks look ready to soar higher from current levels.
HIVE: 6.00 (-0.45), SPHS: 2.51 (-0.54), MOBL: 3.92 (-0.09), SIXD: 2.90 (unch), PRSN: 0.58 (unch)

Drugs - Generic Equities Coverage -- Oculus Innovative Sciences, Medicines, Supernus Pharma, Sophiris Bio, and Rigel Pharma
PR Newswire - Wed Aug 05, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Oculus Innovative Sciences Inc. (NASDAQ: OCLS), The Medicines Company (NASDAQ: MDCO), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Sophiris Bio Inc. (NASDAQ: SPHS), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free research report on Oculus Innovative Sciences can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=OCLS On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69, and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SPHS: 2.51 (-0.54), MDCO: 40.00 (+1.51), SUPN: 16.20 (-0.12), RIGL: 3.05 (-0.01), OCLS: 1.10 (-0.10)

Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 7.91 (+0.14), SPHS: 2.51 (-0.54), NYMX: 3.26 (+0.02), ABBV: 59.86 (-0.37)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu May 28, 8:16AM CDT

RALY: 19.49 (+0.01), KNDI: 9.64 (-0.13), EXPR: 17.10 (-0.89), MNGA: 1.16 (+0.02), SPHS: 2.51 (-0.54), NBS: 2.25 (-0.09), BIOC: 1.96 (+0.02), ONTY: 3.46 (+0.19), OHGI: 1.29 (+0.05), IMAX: 37.66 (-0.91), KNOP: 15.35 (+0.89), CERE: 0.91 (-0.01), DANG: 6.67 (-0.08), XOMA: 1.36 (+0.01)

Sophiris Bio to Present at the LD Micro Invitational Conference
Business Wire - Wed May 27, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the LD Micro Invitational Conference. The presentation is scheduled for Tuesday, June 2, 2015 at 11:30 a.m. PDT in Los Angeles.
SPHS: 2.51 (-0.54)

Sophiris Bio initiates mid-stage trial of lead product candidate PRX302
Seeking Alpha - at Seeking Alpha - Wed May 27, 12:39PM CDT

SPHS: 2.51 (-0.54)

Sophiris Bio admits first patients under Phase 2a proof of concept study of PRX302 in prostate cancer
M2 - Wed May 27, 4:17AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) said on Tuesday that it has dosed the first patients in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer, the second most common form of cancer in men in the US with an estimated 220,800 new cases in 2015.
SPHS: 2.51 (-0.54)

Sophiris Bio Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study
Business Wire - Tue May 26, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that the first patients have been dosed in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer.
SPHS: 2.51 (-0.54)

Sophiris Bio reports Q1 results
Seeking Alpha - at Seeking Alpha - Wed May 13, 3:48PM CDT

SPHS: 2.51 (-0.54)

Sophiris Bio Reports First Quarter Financial Results
Business Wire - Wed May 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2015.
SPHS: 2.51 (-0.54)

Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
RTTR: 2.22 (unch), SPHS: 2.51 (-0.54), ASPX: 100.96 (unch)

Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors
Business Wire - Wed Apr 22, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Gerald T. Proehl has joined the Company's Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company's nominating and corporate governance committee.
TENX: 3.21 (-0.02), RTTR: 2.22 (unch), SPHS: 2.51 (-0.54), SLXP: 172.96 (+0.15)

Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 284.84 (-6.49), SPHS: 2.51 (-0.54), ADMS: 15.74 (+0.58), TKMR: 10.83 (+0.58), CBYL: 3.98 (-0.01), HPTX: 45.99 (+0.02), QURE: 18.85 (-0.12), SHPG: 203.58 (-2.36), SRPT: 25.83 (+0.96), HZNP: 17.99 (+0.38), GALE: 1.50 (+0.02), JUNO: 50.00 (+0.11), ABBV: 59.86 (-0.37), CBMG: 24.59 (+1.23), ARNA: 1.78 (+0.06), EXEL: 5.40 (-0.01), ADXS: 13.36 (+0.47), PTLA: 48.96 (-0.43), BMY: 64.15 (+0.43), OCUL: 8.48 (+0.43), NVO: 52.93 (-0.57), DVA: 72.58 (-0.66), HALO: 15.41 (+0.10), GILD: 102.57 (-1.66), MRK: 53.03 (unch), AZN: 31.29 (+0.44), ALXN: 166.44 (+0.31), NVS: 86.28 (-0.58)

Sophiris Bio - Maybe Not A Left-For-Dead Biotech
JOHN PEABODY - at Seeking Alpha - Thu Apr 09, 3:47PM CDT

SPHS: 2.51 (-0.54)

Biotech Weekly: Why Financials Matter
Daniel Ward - at Seeking Alpha - Mon Apr 06, 8:58AM CDT

SPHS: 2.51 (-0.54), XBI: 68.27 (-0.05), IBB: 323.64 (+3.53), AEZS: 0.05 (unch), EXEL: 5.40 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spire's Year-End Call: Eyes on Earnings & Guidance

Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...

Encompass Health: Leader in Rehabilitation Again in 2026

Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...

Understanding Truck Accident Settlements in Memphis

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

Taiwan Excellence Sparks Smart Automotive Innovation at SEMA

Taiwan's making waves, folks, and it's not your everyday splash in the automotive pool. At SEMA 2026, Taiwan Excellence Pavilion is the place to be with its array of intelligent automotive solutions. This ain't just your run-of-the-mill car show gimmickry—it's the future rolling in real-time. Driving Innovation: From Components to Smart Systems The name of the game is...

New JPA Aims to Energize Inland Empire's Water Supply

Fresh Steps in San Bernardino's Infrastructure Strategy Here's a twist for you: public agencies in San Bernardino County decided enough with the same old, same old and cooked up a new joint powers authority (JPA). They call it the San Bernardino Water and Power Authority, which sounds snappy enough for a meeting room nameplate, I reckon. Who's Steering the Ship? Leading...

Artificial Stone Silicosis: A Silent Threat Unveiled

The Harsh Reality Behind Artificial Stone You're slicing into your steak at a fancy dinner, and for a moment, you marvel at the countertop beneath your dish—a smooth, sleek surface that's likely made of artificial stone. But beneath that lustrous facade lurks a silent killer affecting those fabricating these countertops every day. Voices from the Frontline Recently,...

VISTAR Oakland Workers Join Teamsters for Unity

Warehouse Workers Break Free from the Shackles Ever had that feeling, where enough is enough? That's where 37 warehouse workers at VISTAR find themselves, shaking off the dust and signing up with Teamsters Local 853. This ain't just a fleeting wind of change; it's the whole damn storm. Turning Points and Union Victories Think about it. This move by the VISTAR warehouse...

AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Noé Hinojosa Jr. Honored for Leadership in Business

From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...

Ball Corp's Leadership Shuffle Aims for Strategic Gains

Leadership Changes in the Midst of Market Challenges You don't need a crystal ball to see that leadership changes can signal either turmoil or opportunity. Ball Corporation, a titan in the realm of aluminum packaging, is experiencing a shake-up at the top of its beverage packaging business units. With Carey Causey stepping into the role for North and Central America, and...